R Squared Ltd Acquires New Holdings in Genmab A/S (NASDAQ:GMAB)

R Squared Ltd bought a new position in shares of Genmab A/S (NASDAQ:GMAB) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,440 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GMAB. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Blue Trust Inc. grew its position in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after buying an additional 3,880 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after buying an additional 1,413 shares during the period. Mount Yale Investment Advisors LLC bought a new position in shares of Genmab A/S during the third quarter worth about $192,000. Finally, Signaturefd LLC lifted its stake in shares of Genmab A/S by 32.1% in the third quarter. Signaturefd LLC now owns 7,900 shares of the company’s stock worth $193,000 after acquiring an additional 1,920 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GMAB. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB opened at $19.81 on Friday. Genmab A/S has a one year low of $19.02 and a one year high of $31.88. The company has a market cap of $13.11 billion, a PE ratio of 19.23, a P/E/G ratio of 0.57 and a beta of 0.97. The stock has a 50-day moving average of $21.06 and a 200-day moving average of $23.79.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the prior year, the firm earned $0.47 EPS. Analysts expect that Genmab A/S will post 1.28 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.